The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Research Report 2025

Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1721268

No of Pages : 71

Ask Your Query

Synopsis

Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis.

The global Prostate Specific Antigen (PSA) Blood Based Biomarker market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Prostate Specific Antigen (PSA) Blood Based Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Prostate Specific Antigen (PSA) Blood Based Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Prostate Specific Antigen (PSA) Blood Based Biomarker in Diagnostics is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Prostate Specific Antigen (PSA) Blood Based Biomarker include ProteoMediX, Cleveland Diagnostics, Randox, Roche, GENFIT, Nutech Cancer Biomarkers, OGT (Sysmex Group), Minomic and Creative Diagnostics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Prostate Specific Antigen (PSA) Blood Based Biomarker, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Specific Antigen (PSA) Blood Based Biomarker.

Report Scope

The Prostate Specific Antigen (PSA) Blood Based Biomarker market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Prostate Specific Antigen (PSA) Blood Based Biomarker market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Prostate Specific Antigen (PSA) Blood Based Biomarker companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • ProteoMediX
  • Cleveland Diagnostics
  • Randox
  • Roche
  • GENFIT
  • Nutech Cancer Biomarkers
  • OGT (Sysmex Group)
  • Minomic
  • Creative Diagnostics

Segment by Type

  • Screening Biomarker
  • Diagnosis Biomarker

Segment by Application

  • Diagnostics
  • Drug Discovery
  • Personalized Medicine
  • Others

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Netherlands)
  • Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
  • Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Prostate Specific Antigen (PSA) Blood Based Biomarker companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Screening Biomarker
1.2.3 Diagnosis Biomarker
1.3 Market by Application
1.3.1 Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Diagnostics
1.3.3 Drug Discovery
1.3.4 Personalized Medicine
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Perspective (2019-2030)
2.2 Prostate Specific Antigen (PSA) Blood Based Biomarker Growth Trends by Region
2.2.1 Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Prostate Specific Antigen (PSA) Blood Based Biomarker Historic Market Size by Region (2019-2024)
2.2.3 Prostate Specific Antigen (PSA) Blood Based Biomarker Forecasted Market Size by Region (2025-2030)
2.3 Prostate Specific Antigen (PSA) Blood Based Biomarker Market Dynamics
2.3.1 Prostate Specific Antigen (PSA) Blood Based Biomarker Industry Trends
2.3.2 Prostate Specific Antigen (PSA) Blood Based Biomarker Market Drivers
2.3.3 Prostate Specific Antigen (PSA) Blood Based Biomarker Market Challenges
2.3.4 Prostate Specific Antigen (PSA) Blood Based Biomarker Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Prostate Specific Antigen (PSA) Blood Based Biomarker Players by Revenue
3.1.1 Global Top Prostate Specific Antigen (PSA) Blood Based Biomarker Players by Revenue (2019-2024)
3.1.2 Global Prostate Specific Antigen (PSA) Blood Based Biomarker Revenue Market Share by Players (2019-2024)
3.2 Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Prostate Specific Antigen (PSA) Blood Based Biomarker Revenue
3.4 Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Concentration Ratio
3.4.1 Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prostate Specific Antigen (PSA) Blood Based Biomarker Revenue in 2023
3.5 Prostate Specific Antigen (PSA) Blood Based Biomarker Key Players Head office and Area Served
3.6 Key Players Prostate Specific Antigen (PSA) Blood Based Biomarker Product Solution and Service
3.7 Date of Enter into Prostate Specific Antigen (PSA) Blood Based Biomarker Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Prostate Specific Antigen (PSA) Blood Based Biomarker Breakdown Data by Type
4.1 Global Prostate Specific Antigen (PSA) Blood Based Biomarker Historic Market Size by Type (2019-2024)
4.2 Global Prostate Specific Antigen (PSA) Blood Based Biomarker Forecasted Market Size by Type (2025-2030)
5 Prostate Specific Antigen (PSA) Blood Based Biomarker Breakdown Data by Application
5.1 Global Prostate Specific Antigen (PSA) Blood Based Biomarker Historic Market Size by Application (2019-2024)
5.2 Global Prostate Specific Antigen (PSA) Blood Based Biomarker Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size (2019-2030)
6.2 North America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size by Country (2019-2024)
6.4 North America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size (2019-2030)
7.2 Europe Prostate Specific Antigen (PSA) Blood Based Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size by Country (2019-2024)
7.4 Europe Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size (2019-2030)
8.2 Asia-Pacific Prostate Specific Antigen (PSA) Blood Based Biomarker Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size by Region (2019-2024)
8.4 Asia-Pacific Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size (2019-2030)
9.2 Latin America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size by Country (2019-2024)
9.4 Latin America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size (2019-2030)
10.2 Middle East & Africa Prostate Specific Antigen (PSA) Blood Based Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size by Country (2019-2024)
10.4 Middle East & Africa Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 ProteoMediX
11.1.1 ProteoMediX Company Detail
11.1.2 ProteoMediX Business Overview
11.1.3 ProteoMediX Prostate Specific Antigen (PSA) Blood Based Biomarker Introduction
11.1.4 ProteoMediX Revenue in Prostate Specific Antigen (PSA) Blood Based Biomarker Business (2019-2024)
11.1.5 ProteoMediX Recent Development
11.2 Cleveland Diagnostics
11.2.1 Cleveland Diagnostics Company Detail
11.2.2 Cleveland Diagnostics Business Overview
11.2.3 Cleveland Diagnostics Prostate Specific Antigen (PSA) Blood Based Biomarker Introduction
11.2.4 Cleveland Diagnostics Revenue in Prostate Specific Antigen (PSA) Blood Based Biomarker Business (2019-2024)
11.2.5 Cleveland Diagnostics Recent Development
11.3 Randox
11.3.1 Randox Company Detail
11.3.2 Randox Business Overview
11.3.3 Randox Prostate Specific Antigen (PSA) Blood Based Biomarker Introduction
11.3.4 Randox Revenue in Prostate Specific Antigen (PSA) Blood Based Biomarker Business (2019-2024)
11.3.5 Randox Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche Prostate Specific Antigen (PSA) Blood Based Biomarker Introduction
11.4.4 Roche Revenue in Prostate Specific Antigen (PSA) Blood Based Biomarker Business (2019-2024)
11.4.5 Roche Recent Development
11.5 GENFIT
11.5.1 GENFIT Company Detail
11.5.2 GENFIT Business Overview
11.5.3 GENFIT Prostate Specific Antigen (PSA) Blood Based Biomarker Introduction
11.5.4 GENFIT Revenue in Prostate Specific Antigen (PSA) Blood Based Biomarker Business (2019-2024)
11.5.5 GENFIT Recent Development
11.6 Nutech Cancer Biomarkers
11.6.1 Nutech Cancer Biomarkers Company Detail
11.6.2 Nutech Cancer Biomarkers Business Overview
11.6.3 Nutech Cancer Biomarkers Prostate Specific Antigen (PSA) Blood Based Biomarker Introduction
11.6.4 Nutech Cancer Biomarkers Revenue in Prostate Specific Antigen (PSA) Blood Based Biomarker Business (2019-2024)
11.6.5 Nutech Cancer Biomarkers Recent Development
11.7 OGT (Sysmex Group)
11.7.1 OGT (Sysmex Group) Company Detail
11.7.2 OGT (Sysmex Group) Business Overview
11.7.3 OGT (Sysmex Group) Prostate Specific Antigen (PSA) Blood Based Biomarker Introduction
11.7.4 OGT (Sysmex Group) Revenue in Prostate Specific Antigen (PSA) Blood Based Biomarker Business (2019-2024)
11.7.5 OGT (Sysmex Group) Recent Development
11.8 Minomic
11.8.1 Minomic Company Detail
11.8.2 Minomic Business Overview
11.8.3 Minomic Prostate Specific Antigen (PSA) Blood Based Biomarker Introduction
11.8.4 Minomic Revenue in Prostate Specific Antigen (PSA) Blood Based Biomarker Business (2019-2024)
11.8.5 Minomic Recent Development
11.9 Creative Diagnostics
11.9.1 Creative Diagnostics Company Detail
11.9.2 Creative Diagnostics Business Overview
11.9.3 Creative Diagnostics Prostate Specific Antigen (PSA) Blood Based Biomarker Introduction
11.9.4 Creative Diagnostics Revenue in Prostate Specific Antigen (PSA) Blood Based Biomarker Business (2019-2024)
11.9.5 Creative Diagnostics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock